Swiss pharma giants fined by France in ongoing eye drug clash
The two drugs are used to to treat patients with blindness-causing macular degeneration.
Keystone/Jay
The pharmaceutical companies Novartis and Roche have been fined €444 million (CHF481 million) by the French competition authority for applying abusive practices to push costly eye injection Lucentis over a cheaper drug.
This content was published on
2 minutes
swissinfo.ch with Reuters/ug
Português
pt
França processa farmacêuticas suíças por injeção de colírio
The two Swiss pharma companies abused their dominant position to push Lucentis at the expense of the drug Avastin, the French competition watchdog announced on Wednesday.
It added that Novartis was also punished for “unjustifiably exaggerating” Avastin’s risks.
Novartis, which said it would appeal, is facing high stakes in protecting Lucentis sales in Europe, after the uptake of its newest eye drug, Beovu, has been slowed by safety concerns.
Novartis must pay €385 million and Roche about €60 million, according to the decision.
Roche and Novartis are partners on Lucentis, with Roche selling it in the United States and Novartis selling it in Europe.
Running battle
The fines are the latest development in a running battle between the drug makers and countries where some doctors have turned to Roche’s cheaper Avastin to replace costly Lucentis, to treat patients with blindness-causing macular degeneration (AMD).
Lucentis was developed for AMD but works like cancer drug Avastin by inhibiting blood vessel growth. Avastin is used “off-labelExternal link” to treat AMD.
The French authority said Lucentis, injected roughly once per month, costs €1,161 per injection, while Avastin runs at €30 to €40 per shot.
Similar disputes have emerged elsewhere. In 2018, Novartis and Roche lost a bid in Britain to block doctors from making Avastin the preferred option for AMD.
RocheExternal link said it was disappointed and would “assess” the situation.
NovartisExternal link said a French rule allowing off-label use of medicines in diseases with approved treatments threatens the system of ensuring safe and effective drugs.
“This decision relies on a gross misinterpretation of the facts and a distortion of previous case law,” Novartis said.
Popular Stories
More
Aging society
Is Switzerland repeating England’s housing mistakes?
Train vs plane: would you take a direct train between London and Geneva?
Eurostar is planning to run direct trains from Britain to Germany and Switzerland from the early 2030s. Would you favour the train over the plane? If not, why not?
Zurich arbitration authority rules in favour of tenants of ‘Sugus Houses’
This content was published on
A conciliation authority says the terminations of 105 flat leases in the so-called "Sugus Houses" in the centre of Zurich were abusive. The tenants therefore do not have to move out - at least for the time being.
This content was published on
Visitors to Switzerland spent CHF19.6 billion ($23.9 billion) last year, a 2.2% rise compared to the previous year, the Federal Statistical Office (FSO) said on Monday.
This content was published on
Despite the current tense economic situation, Swiss consumer sentiment remains positive. The Swiss spent more money in May than the previous year, particularly on restaurant visits and leisure activities, as shown by the latest figures released by PostFinance.
This content was published on
A bear killed four sheep in the Lower Engadine region near Scuol, canton Graubünden, last week. This was the first bear attack on local livestock in four years.
This content was published on
Experts believe that economic development in Switzerland will be weaker in 2026 than the forecasts made three months ago. They have also lowered their predictions for the current year.
This content was published on
Fewer people in Switzerland have a religious affiliation and the proportion who practice their religion regularly is steadily declining, a survey finds.
Study: trees have major cooling effect even in extreme heat
This content was published on
Plane trees in cities have an important cooling effect even in extreme heat, according to a new study by the Swiss Federal Institute for Forest, Snow and Landscape Research (WSL).
EPFL launches digitised version of Battle of Murten panorama
This content was published on
To mark the anniversary of the Battle of Murten on 22 June 1476, the Federal Institute of Technology Lausanne (EPFL) has launched a website that offers the public an immersive experience of the huge panorama painting of the historic battle.
77th Swiss Gymnastics Festival praised for ‘positive energy’
This content was published on
The 77th Federal Gymnastics Festival drew to a close on Sunday in Lausanne, after eleven days of popular celebration and sporting performances.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Roche clears drug that caused vision loss in India
This content was published on
“In India, Roche has completed an assessment of the available information on the batch reported to have been used at C.H Nagri Eye Hospital in Ahmedabad, Gujarat. We can confirm that based on the information available, there is no reason to believe there were quality problems with the Avastin (Bevacizumab) vials in this batch,” a…
Novartis pays big fine for bribing doctors in the US
This content was published on
Swiss pharma company Novartis will pay $729 million to US authorities in an out-of-court settlement over charges that the company bribed doctors to use its drugs.
Can big pharma’s money solve the antibiotics crisis?
This content was published on
Big pharmaceutical companies are investing nearly $1 billion in a fund to bring new antibiotics to patients. What's the catch?
Are Big Pharma’s big innovation plans what we need?
This content was published on
Our analysis of what the biggest global companies in Switzerland are up to. This week: Big Pharma's R&D plans, coronavirus impact, and #cryptoleaks.
Big companies get ready for a contentious political season
This content was published on
Our analysis of what the biggest global companies in Switzerland are up to. This week: companies mixed up in politics and foreign aid.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.